These data led them to propose that specifically CB2 presented an independent prognostic factor for the overall survival of RCC patients, and the use of CB2 inverse agonists or antagonists could serve as a novel pharmacological strategy in RCC [197]. The gene discussed is CNR2; the disease is renal cell carcinoma.